KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Financing Activities (2016 - 2025)

Sarepta Therapeutics has reported Cash from Financing Activities over the past 15 years, most recently at -$39.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 180.03% year-over-year to -$39.2 million; the TTM value through Dec 2025 reached -$168.3 million, down 234.88%, while the annual FY2025 figure was -$168.3 million, 234.88% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$39.2 million at Sarepta Therapeutics, up from -$117.8 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $549.2 million in Q4 2021 and troughed at -$117.8 million in Q3 2025.
  • A 5-year average of $43.8 million and a median of $8.3 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 3567.05% in 2022 and later crashed 956.22% in 2025.
  • Year by year, Cash from Financing Activities stood at $549.2 million in 2021, then plummeted by 98.04% to $10.7 million in 2022, then crashed by 81.92% to $1.9 million in 2023, then surged by 2421.41% to $49.0 million in 2024, then plummeted by 180.03% to -$39.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for SRPT at -$39.2 million in Q4 2025, -$117.8 million in Q3 2025, and -$23.8 million in Q2 2025.